Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and to determine the maximum tolerated dose of
carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple
Myeloma patients who have not received treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborators:
Celgene Celgene Corporation Onyx Therapeutics, Inc.